PGIM India Healthcare Fund Direct Growth Review 2026: NAV, Returns, Portfolio & Should You Invest?
- September 16, 2026
- Posted by: Chaitanya Auti
- Category: Mutual Funds
PGIM India Healthcare Fund Direct Growth Plan has a NAV of ₹12.34 as of 15 Sep 2026 and an AUM of ₹125 Cr. Its 1-year, 3-year and 5-year returns are 24.53%, 0% and 0%, and the scheme is tagged as High Risk. Our view is that the fund has shown strong short-term momentum, but the very short track record and the absence of longer trailing history make it better suited to investors who can accept sector-level volatility.
The portfolio is tilted toward healthcare names, with a meaningful cash and cash-equivalent sleeve among the leading holdings. That mix can support resilience, but it also means returns may move sharply with healthcare stock selection and sector sentiment rather than broad market trends.
Quick facts
| Particular | Details |
|---|---|
| NAV | ₹12.34 as of 15 Sep 2026 |
| AUM | ₹125 Cr |
| Expense Ratio | 0.66% |
| Launch Date | 06 Dec 2024 |
| Min SIP | ₹1,000 |
| Risk Category | High Risk |
| Benchmark | Nifty 50 |
| Fund Category | Equity |
| Exit Load | 0.50% on or before 90D, Nil after 90D |
| Fund Managers | Anandha Padmanabhan Anjeneyan, Utsav Mehta, Sharma Vivek, Puneet Pal |
The fund is managed by Anandha Padmanabhan Anjeneyan, Utsav Mehta, Sharma Vivek and Puneet Pal.
Source data date: as of 15 Sep 2026
Performance
| Period | Fund return | Benchmark return |
|---|---|---|
| 1M | -1.28% | -4.81% |
| 3M | 10.08% | -3.63% |
| 1Y | 24.53% | -8.27% |
| 3Y | Data not available | Data not available |
| 5Y | Data not available | Data not available |
The short-end performance has been uneven, but the fund has recovered better than the benchmark over every available period. The 1-month return was slightly negative, yet it still held up better than the benchmark’s sharper decline. Over 3 months, the fund turned in a clear gain while the benchmark stayed in negative territory, which points to stronger recent stock selection within the portfolio.
The 1-year figure is the most useful anchor at this stage. A 24.53% return against the benchmark’s -8.27% indicates that the fund has materially outpaced the broad market reference over the last year. That said, the series also shows short bursts of softness along the way, so the path has not been linear.
Because the scheme was launched on 06 Dec 2024, there is no meaningful 3-year or 5-year track record to study yet. For us, that means the current picture is dominated by near-term behaviour rather than a full cycle. Investors should treat the recent strength as encouraging, but not as proof of consistency through different market environments.
Source data date: as of 15 Sep 2026
Should you BUY or HOLD PGIM India Healthcare?
A fund’s past returns alone don’t tell you whether you should buy it today or continue holding it.
The right decision depends on factors such as your current allocation, purchase price, risk profile, investment horizon and the role this fund plays in your overall portfolio.
Already holding PGIM India Healthcare? Thinking of investing now?
Peer comparison
| Fund | 1Y return | 3Y return | 5Y return |
|---|---|---|---|
| PGIM India Healthcare Fund Direct Growth Plan | 24.53% | Data not available | Data not available |
| ICICI Pru Strategic Metal and Energy Equity FoF Direct Growth Plan | 69.16% | 37.12% | Data not available |
| Motilal Oswal Active Momentum Fund Direct Growth Plan | 30.67% | Data not available | Data not available |
| Kotak Healthcare Fund Direct Growth Plan | 28.09% | Data not available | Data not available |
| HDFC Pharma and Healthcare Fund Direct Growth Plan | 27.47% | Data not available | Data not available |
| SBI Automotive Opportunities Fund Direct Growth Plan | 27.05% | Data not available | Data not available |
This assessment is prepared by Uniapps Investment Adviser Pvt. Ltd. under SEBI Registered Investment Adviser registration INA000017639. The fund’s 1-year return trails the strongest peer figure listed here, but it remains in the same broad range as several other healthcare-oriented or sector-focused options on a one-year view. Where this scheme stands out is less in absolute upside and more in the way it has stayed ahead of the benchmark while still showing some short-term fluctuation.
On the longer horizon, the comparison is limited because the scheme itself does not yet have usable 3-year or 5-year figures. That means the peer set offers more history than the fund does, so the main takeaway is that recent strength has not yet been tested across longer market cycles. The short-term picture and the absence of longer trailing data tell different stories: one shows momentum, the other shows that the evidence base is still building.
Source data date: as of 15 Sep 2026
Want to know more? Log in to Univest for more mutual fund insights.
Portfolio: where your money goes
| Holding | Sector | Weight |
|---|---|---|
| Divi’S Laboratories Ltd. | Healthcare | 10.85% |
| Sun Pharmaceutical Industries Ltd. | Healthcare | 10.74% |
| Torrent Pharmaceuticals Ltd. | Healthcare | 8.86% |
| Clearing Corporation of India Ltd. | Cash & Cash Equivalents and Net Assets | 5.76% |
| Max Healthcare Institute Ltd. | Healthcare | 4.96% |
| Ajanta Pharma Ltd. | Healthcare | 4.83% |
| Manipal Health Enterprises Ltd. | Domestic Equities | 4.12% |
| Mankind Pharma Ltd. | Healthcare | 4.07% |
| Rubicon Research Ltd. | Domestic Equities | 4.01% |
| DR. Lal Path Labs Ltd. | Healthcare | 3.93% |
The largest disclosed holding, Divi’S Laboratories Ltd., accounts for 10.85% of the portfolio, and the next two names are also close to double-digit weight. That tells us the portfolio is anchored by a few sizeable positions rather than being evenly spread across many names.
Weight then tapers gradually rather than collapsing after the top three. By the tenth holding, the weight is still 3.93%, which suggests the portfolio keeps meaningful exposure across several healthcare businesses instead of relying on one dominant stock. The presence of a 5.76% cash and cash-equivalent position among the top holdings may also reduce day-to-day swings at the margin.
At 62.13% for the top 10 holdings, the disclosed part of the portfolio is fairly concentrated, and the scheme still has 31 disclosed holdings in total. That combination suggests a core of high-conviction positions with a longer tail of smaller exposures, so individual stock moves could matter more than in a highly diversified broad-market fund.
To see all holdings, visit the PGIM India Healthcare Fund Direct Growth Plan page
Source data date: as of 15 Sep 2026
Who should invest
This fund suits investors who can live with High Risk exposure and who are comfortable with a sector-focused equity theme. The 1-year performance has been clearly better than the benchmark, but the scheme is still too new for a longer history to be treated as stable through cycles.
The cleaner fit is for a medium- to long-term horizon, where healthcare-specific volatility can be absorbed. The main trade-off is that the fund may deliver periods of strong relative outperformance, but it may also move sharply when healthcare stock sentiment turns or when a few large positions behave unevenly.
Tax and exit load
| Holding period | Tax rate | Description |
|---|---|---|
| Units held less than 1 year | 20% | Short-term capital gains tax |
| Units held more than 1 year | 12.5% | Long-term capital gains tax |
Exit load: 0.50% on or before 90D, Nil after 90D.
Source data date: as of 15 Sep 2026
Frequently asked questions
What is the current NAV of PGIM India Healthcare Fund Direct Growth Plan?
Its current NAV is ₹12.34 as of 15 Sep 2026.
What are the fund’s 1-year, 3-year and 5-year returns?
The fund’s 1-year return is 24.53%, while the 3-year and 5-year returns are Data not available because the scheme is still very new.
How has it performed against the benchmark?
It has outperformed the benchmark over every available period. The gap is especially clear over 1 year, where the fund returned 24.53% and the benchmark returned -8.27%.
How does it compare with the peer funds listed here?
Its 1-year return is below the strongest peer figure in the list, but it is close to several other healthcare or thematic funds on a one-year view. The longer-term comparison is limited because the scheme does not yet have usable 3-year or 5-year figures.
Is there a minimum SIP amount?
Yes, the minimum SIP amount is ₹1,000.
What should investors know about risk, holdings and exit load?
The scheme is marked High Risk and has a healthcare-heavy portfolio, led by Divi’S Laboratories Ltd. at 10.85% and Sun Pharmaceutical Industries Ltd. at 10.74%. The exit load is 0.50% on or before 90D and nil after 90D.
Bottom line
PGIM India Healthcare Fund Direct Growth Plan has shown stronger recent returns than its benchmark, but it is still too early to call the pattern established over longer cycles. Compared with the listed peers, the 1-year return is respectable but not the highest, while the absence of usable 3-year and 5-year figures limits deeper comparison. The portfolio is concentrated in healthcare names, with a few large positions carrying meaningful weight, so the fund is best read as a high-risk sector strategy for investors who can tolerate uneven short-term moves.
Published on 16 September 2026 at 8:07 AM IST
Explore mutual funds with Univest
Review mutual fund data, compare performance and explore fund insights on Univest.
RIA disclosure
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully before investing. This review is prepared by Uniapps Investment Adviser Pvt. Ltd. (earlier known as Uniapps Global Research Pvt. Ltd.) under SEBI Registered Investment Adviser registration INA000017639 for general informational purposes and is not personalized investment advice.